Medicrea Reports First Half 2019 Sales - Seite 2

The first half of 2019 demonstrated record activity for UNiD patient-specific rods. The milestone of 4,000 surgeries performed has been achieved, with 423 surgeries in the 2^nd quarter of 2019. In the month of June alone, 171 personalized UNiD surgeries were performed and a new monthly record should be established in July.

The adoption of UNiD ASI technology for patient-specific spinal surgery is accelerating rapidly quarter-over-quarter. The following graph shows the evolution of total UNiD surgeries over a rolling 4-quarter period. Over the last 18 months, the increase exceeds 80% (825 surgeries performed over the last 4 quarters at the end of Q4 2017 versus 1,510 at the end of Q2 2019).

Outlook

The increasing use of expert pre-operative planning and patient analysis services by the UNiD Lab engineering teams using the proprietary UNiD platform represents a significant revenue potential for Medicrea due to two opportunities:

- UNiD patient-specific rods are systematically implanted with associated implants (screws, connectors) marketed by the Company. This is currently the case for only 50% of UNiD surgeries in the United States due to surgeons implanting "Tulip-based” pedicle screw systems from their historical suppliers in combination with Medicrea's UNiD patient-specific rods. A steady increase of this ratio will allow Medicrea to significantly increase its revenue in this market, especially since the Company now has a product portfolio that adapts to all surgeons’ practices, particularly since the FDA approval of its new Tulip Genesis screw system, whose first kits have just been delivered in the United States for its commercial launch in Q3 2019. This recent approval from the FDA will be a key growth driver for the Company and will be announced in detail within the next few days.

- In order to enhance innovation and accelerate the monetization of the expert services powered by the predictive model and Artificial Intelligence developed on the clinical database collected by the UNiD ASI platform, Medicrea also plans to invoice UNiD patient-specific rod planning services in the USA, and not just the implants that result from surgical planning.

“We have developed an unparalleled surgical planning software platform that positions us as a unique player in personalized spine surgery. Thanks to the UNiD ASI technology and the skills of our UNiD Lab engineers, we dramatically improve the standard of care of spinal pathologies by offering a solution adapted to each patient. This offer brings significant added value to our customers. We will continue to deploy capital expenditures and resources to accelerate the adoption of this technology”, commented Denys Sournac, President and CEO of Medicrea.